Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $19.70 Consensus PT from Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been assigned an average rating of “Hold” from the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $19.70.

AARD has been the subject of several recent research reports. HC Wainwright reiterated a “neutral” rating on shares of Aardvark Therapeutics in a research report on Monday, March 2nd. B. Riley Financial reduced their price target on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Royal Bank Of Canada cut Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $18.00 to $6.00 in a research report on Monday, March 2nd. BTIG Research cut Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Finally, Weiss Ratings cut Aardvark Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 27th.

Aardvark Therapeutics Stock Up 0.2%

Shares of NASDAQ:AARD opened at $3.94 on Monday. Aardvark Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.94. The stock has a market cap of $85.95 million, a price-to-earnings ratio of -1.23 and a beta of 4.47. The business has a 50-day moving average price of $4.66 and a 200-day moving average price of $8.66.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share for the quarter. As a group, equities analysts anticipate that Aardvark Therapeutics will post -3.46 EPS for the current fiscal year.

Institutional Trading of Aardvark Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AARD. Goldman Sachs Group Inc. purchased a new stake in shares of Aardvark Therapeutics in the first quarter valued at approximately $153,000. Geode Capital Management LLC increased its position in shares of Aardvark Therapeutics by 129.7% in the second quarter. Geode Capital Management LLC now owns 136,927 shares of the company’s stock valued at $1,851,000 after buying an additional 77,327 shares in the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Aardvark Therapeutics in the second quarter valued at approximately $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Aardvark Therapeutics in the second quarter valued at approximately $42,000. Finally, Bank of America Corp DE increased its position in shares of Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after buying an additional 3,369 shares in the last quarter.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.